Avidity Biosciences (Nasdaq:RNA) - Aandelenkoers, Nieuws & Analyse

RNA Overzicht aandelen

Avidity Biosciences, Inc. is een biofarmaceutisch bedrijf dat zich bezighoudt met de levering van RNA-therapeutica.

RNA fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Trading at 68.9% below our estimate of its fair value

Revenue is forecast to grow 64.16% per year

Risicoanalyse

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Avidity Biosciences, Inc. Concurrenten

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$4.7b

Biohaven

NYSE:BHVN

US$5.1b

IVERIC bio

NasdaqGS:ISEE

US$5.5b

Immunovant

NasdaqGS:IMVT

US$4.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avidity Biosciences
Historische aandelenkoersen
Huidige aandelenkoers	US$41.87
52 Week Hoogtepunt	US$50.78
52 Week Laag	US$5.15
Bèta	0.89
11 maand verandering	-11.48%
3 maanden verandering	-4.43%
1 Jaar Verandering	690.00%
33 jaar verandering	62.85%
5 jaar verandering	n/a
Verandering sinds IPO	46.91%

Recent nieuws en updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Aug 11

Recent updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26

Avidity Biosciences: Risks And Potential

Dec 09

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Nov 30

Rendement voor aandeelhouders

	RNA	US Biotechs	US Markt
7D	-8.4%	-0.7%	-1.6%
1Y	690.0%	19.8%	30.8%

Rendement versus industrie: RNA exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: RNA exceeded the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: RNA has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: RNA's weekly volatility (9%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	253	Sarah Boyce	www.aviditybiosciences.com

Avidity Biosciences, Inc., een biofarmaceutisch bedrijf, houdt zich bezig met de toediening van RNA-therapeutica. Het ontwikkelt oligonucleotideconjugaten met antilichamen (AOC) die ontworpen zijn om ziekten te behandelen die voorheen onbehandelbaar waren met RNA-therapeutica. De belangrijkste productkandidaat van het bedrijf, AOC 1001, voor de behandeling van myotone dystrofie type 1, een zeldzame monogene spierziekte die zich in fase 1/2 van de klinische studie bevindt.

Avidity Biosciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Avidity Biosciences zich tot de beurswaarde?
RNA fundamentele statistieken
Marktkapitalisatie	US$4.90b
Inkomsten(TTM)	-US$252.45m
Inkomsten(TTM)	US$10.60m

462.7x

P/S-verhouding

-19.4x

Koers/Winstverhouding

Is RNA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RNA resultatenrekening (TTM)
Inkomsten	US$10.60m
Kosten van inkomsten	US$231.30m
Brutowinst	-US$220.70m
Overige uitgaven	US$31.75m
Inkomsten	-US$252.45m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.16
Brutomarge	-2,082.31%
Nettowinstmarge	-2,381.82%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde RNA op de lange termijn?

Bekijk historische prestaties en vergelijking

RNA Overzicht aandelen

Beloningen

Risicoanalyse

Avidity Biosciences, Inc. Concurrenten

NasdaqGS:RARE

US$4.7b

NYSE:BHVN

US$5.1b

NasdaqGS:ISEE

US$5.5b

NasdaqGS:IMVT

US$4.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Recent updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophin Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial

Avidity Biosciences, Inc. Announces Executive Changes

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold